Bristol, UK, May 7: Scarlet Therapeutics (“Scarlet”) today announced a major preclinical breakthrough in its proprietary cell-line derived, universal, lab-grown red blood cells (RBCs), demonstrating successful maturation and in vivo circulation with a half-life comparable to that of normal donated red blood cells.
Importantly, Scarlet’s engineered RBCs are designed to be universally compatible, eliminating the need for blood-type matching and offering a single scalable product capable of serving a broad patient population. This development represents a significant step toward overcoming long-standing limitations in traditional blood transfusion systems.
Seed Funding to Accelerate Clinical Pathway
Alongside this milestone, Scarlet has successfully closed a £3.2 million seed financing round (approximately USD 4 million). The funds will support in vivo proof-of-concept studies, advancement of manufacturing capabilities, and regulatory engagement as the company progresses toward clinical development.
The round was led by Eos Advisory, with participation from existing investor SCVC, and new investors Oshen Bio (Switzerland & Luxembourg) and Daft Capital (United States).
Platform Technology with Multiple Applications
Scarlet’s RBC platform is designed to enable three key therapeutic and clinical applications:
- Treat: Long-acting therapeutic RBCs engineered for serious diseases
- Transfuse: Universal, off-the-shelf blood products independent of donor supply and blood-type compatibility
- Enhance: Next-generation RBCs designed for potential performance enhancement applications
Leadership Commentary
Alistair Irvine, Chief Executive Officer of Scarlet Therapeutics, said:
“Demonstrating that our lab-grown RBCs can mature and circulate in vivo, with a half-life matching donated blood, is a pivotal validation of what we are building. Our proprietary cell line technology enables scalable, universal RBC manufacturing and opens the door to a new class of durable therapeutics and transfusion products. This financing positions us strongly to select our lead therapeutic candidate and move toward the clinic.”
Harry Destecroix, Managing Partner of SCVC, commented:
“These results mark a major milestone for Scarlet. Moving from concept to in vivo validation is a genuine inflection point. Scarlet has the science and ambition to become a defining company in engineered red blood cells.”
Anne Muir, Director of Portfolio at Eos, added:
“The potential of a universal, scalable red blood cell platform free from donor dependency is remarkable. Scarlet is developing technology that could transform the treatment of serious diseases, and we are proud to have led this round.”
Board Appointments
Scarlet Therapeutics also announced the appointment of three new members to its Board of Directors:
- John Beadle (Eos Advisory)
- Didier Cowling (Oshen Bio)
- Tim Sparey (Independent Chair)
